Global Specialty Pharmaceutical Partnering Terms and Agreements 2014-2020: Deal trends, players and financials


Global Specialty Pharmaceutical Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 

Publication date
March 2020
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Global Specialty Pharmaceutical Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 


This report provides details of the latest specialty pharmaceutical agreements announced in the life sciences since 2014.


The report takes the reader through a comprehensive review specialty specialty pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering specialty pharmaceutical partnering deals.


The report presents financial deal term values for specialty pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.


The middle section of the report explores the leading dealmakers in the specialty pharmaceutical partnering field; both the leading deal values and most active specialty pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.


One of the key highlights of the report is that over 900 online deal records of actual specialty pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.


In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


The initial chapters of this report provide an orientation of specialty pharmaceutical dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in specialty pharmaceutical dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading specialty pharmaceutical deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in specialty pharmaceutical dealmaking with a brief summary followed by a comprehensive listing of specialty pharmaceutical deals announded by that company, as well as contract documents, where available.


Chapter 5 provides a comprehensive and detailed review of specialty pharmaceutical partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of specialty pharmaceutical partnering deals signed and announced since Jan 2014. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


A comprehensive series of appendices is provided organized by specialty pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in specialty pharmaceutical partnering and dealmaking since 2014.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of specialty pharmaceutical technologies and products.


Key benefits


Global Specialty Pharmaceutical Partnering 2014-2020: Deal trends, players, financials and forecasts provides the reader with the following key benefits:


  • In-depth understanding of specialty pharmaceutical deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of specialty pharmaceutical agreements with real life case studies
  • Detailed access to actual specialty pharmaceutical contracts entered into by leading biopharma companies
  • Identify most active specialty pharmaceutical dealmakers since 2014
  • Insight into terms included in a specialty pharmaceutical partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Specialty Pharmaceutical Partnering 2014-2020: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to specialty pharmaceutical trends and structure of deals entered into by leading companies worldwide.


Specialty Pharmaceutical Partnering Terms and Agreements includes:


  • Trends in specialty pharmaceutical dealmaking in the biopharma industry since 2014
  • Analysis of specialty pharmaceutical deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life specialty pharmaceutical deals
  • Access to specialty pharmaceutical contract documents
  • Leading specialty pharmaceutical deals by value since 2014
  • Most active specialty pharmaceutical dealmakers since 2014


In Global Specialty Pharmaceutical Partnering 2014-2020: Deal trends, players, financials and forecasts, the available deals are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Specialty Pharmaceutical Partnering 2014-2020: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for specialty pharmaceutical deals.


Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Specialty Pharmaceutical Partnering 2014-2020: Deal trends, players, financials and forecasts provides the reader with the following key benefits:


  • In-depth understanding of specialty pharmaceutical deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of specialty pharmaceutical agreements with real life case studies
  • Detailed access to actual specialty pharmaceutical contracts entered into by leading biopharma companies
  • Identify most active specialty pharmaceutical dealmakers since 2014
  • Insight into terms included in a specialty pharmaceutical partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in specialty pharmaceutical dealmaking


2.1. Introduction

2.2. Specialty pharmaceutical partnering over the years

2.3. Most active specialty pharmaceutical dealmakers

2.4. Specialty pharmaceutical partnering by deal type

2.5. Specialty pharmaceutical partnering by therapy area

2.6. Specialty pharmaceutical partnering by technology type

2.7. Deal terms for specialty pharmaceutical partnering

2.7.1 Specialty pharmaceutical partnering headline values

2.7.2 Specialty pharmaceutical deal upfront payments

2.7.3 Specialty pharmaceutical deal milestone payments

2.7.4 Specialty pharmaceutical royalty rates


Chapter 3 – Leading specialty pharmaceutical deals


3.1. Introduction

3.2. Top specialty pharmaceutical deals by value


Chapter 4 – Most active specialty pharmaceutical dealmakers


4.1. Introduction

4.2. Most active specialty pharmaceutical dealmakers

4.3. Most active specialty pharmaceutical partnering company profiles


Chapter 5 – Specialty pharmaceutical contracts dealmaking directory


5.1. Introduction

5.2. Specialty pharmaceutical contracts dealmaking directory


Chapter 6 – Specialty pharmaceutical dealmaking by technology type


Chapter 7 – Partnering resource center


7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking




Appendix 1 – Specialty pharmaceutical deals by company A-Z

Appendix 2 – Specialty pharmaceutical deals by stage of development

Appendix 3 – Specialty pharmaceutical deals by deal type

Appendix 4 – Specialty pharmaceutical deals by therapy area

Appendix 5 – Deal type definitions


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: Specialty pharmaceutical partnering since 2014

Figure 2: Active specialty pharmaceutical dealmaking activity since 2014

Figure 3: Specialty pharmaceutical partnering by deal type since 2014

Figure 4: Specialty pharmaceutical partnering by disease type since 2014

Figure 5: Specialty pharmaceutical partnering by technology type since 2014

Figure 6: Specialty pharmaceutical deals with a headline value

Figure 7: Specialty pharmaceutical deals with an upfront value

Figure 8: Specialty pharmaceutical deals with a milestone value

Figure 9: Specialty pharmaceutical deals with a royalty rate value

Figure 10: Top specialty pharmaceutical deals by value since 2014

Figure 11: Most active specialty pharmaceutical dealmakers since 2014

Pricing options


  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

5LINX, 8E6Tong, 22nd Century, 48North Cannabis, Abacus International, Abattis Bioceuticals, Abba Import Export, Abba Medix, Abbott Laboratories, Abbvie, Abic Marketing, Ability Pharmaceuticals, AB InBev, Abiogen Pharma, Ablynx, Accelis Pharma, Acerus, Aceto Corporation, Achieve Life Science, Aclaris Therapeutics, Acnos Pharma, Acorda Therapeutics, Acres Cannabis, Actavis (acquired by Watson), Actavis (name changed to Allergan), Actavis Foshan, Acura Pharmaceuticals, AdAlta, Adamis Pharmaceuticals, Adaptive Biotechnologies, Adapt Pharma, Adare Pharmaceuticals, Adcock Ingram, Addex Therapeutics, ADL Bionatur Solutions, ADMA Biologics, Advanced Accelerator Applications, Advanced Dosage Forms, Advanced Extraction Systems, Advanced Medical Solutions, Advance Pharmaceutical, Advanz Pharma, Advicenne, Aegis Therapeutics, Aeon Bioscience, Aequus Pharmaceuticals, Aerial BioPharma, Aerie Pharmaceuticals, Aesthetic Management Partners, Aevum Life Science, AFT Pharmaceuticals, Agile Therapeutics, AgMedica Bioscience, AgriCann Solutions, Akkadeas Pharma, Akorn, Akums Drugs and Pharmaceuticals, Albany Molecular Research, Alberta Health Services, Albion, Albireo, Aleafia Health, Alfasigma, Algae Dynamics, Alimentary Health, ALK-Abello, Allegis Holdings, Allegro Ophthalmics, Allergan, Alliance Pharma, AllianceRx Walgreens Prime, Allied Corp, Allied Laboratories, All Star Health Brands, Almirall, Alnylam Pharmaceuticals, Altan Pharma, Alternavida, Altus Formulation, Alvit LCS Pharma, Alvogen, Alvotech, Amag Pharmaceuticals, Amarantus BioSciences, Amarillo Biosciences, Amarin, Ambrosia Nutraceuticals, Amend Surgical, American Medical Systems, AmeriCann, American Regent, AmerisourceBergen, Amherst Pharmaceuticals, Amneal Pharmaceuticals, AMO Pharma, AMP German Cannabis, Amphastar Pharmaceuticals, Ampio Pharmaceuticals, Amyris, Anahit, ANANDA Scientific, AnaptysBio, Andromeda Biotech, Andrus, Angelini Pharma, ANI Pharmaceuticals, AOP Orphan Pharmaceuticals, Aperion Biologics, Apex Global Brands, Aphria, Apicore, Apollo Green, Apotex, AppianRx, Applied DNA Sciences, APR Applied Pharma Research, Apricus Biosciences, APS Healthcare, Aptuit, Aqua Pharmaceuticals, Aquestive Therapeutics, Aradigm, Aralez Pharmaceuticals, AR Brown, Ardelyx, Arena Pharmaceuticals, Ariad Pharmaceuticals, Aries Pharmaceuticals, Arjuna Naturals, ArmaGen, Armas Pharmaceuticals, Armetheon, Army & Air Force Exchange Service, Asahi Kasei, Asana Biosciences, Ascendia Pharmaceuticals, Ascend Therapeutics, Asceneuron, Aseptix, ASKA Pharmaceuticals, Aspen Global, Aspen Holding, Assuta Medical Centers, Astellas Pharma US, AstraZeneca, Athenex, Atlangram, Atlantic Healthcare, Aucta Pharmaceuticals, Aura Biosciences, Auris Medical, Aurobindo Pharma, Aurora Cannabis, Authentic Brands Group, Auxly Cannabis Group, Avadel Pharmaceuticals, Avanos Medical, AV Cannabis, Avicanna, Avion Pharmaceuticals, Avondale Pharmaceuticals, Avrio Biopharmaceuticals, AXIM Biotechnologies, Axxess Pharma, Aytu BioScience, Bachem, BAS Research, Battelle, Baxalta, Baxter International, Bayer, Bazelet, Beckley Canopy Therapeutics, Beckley Foundation, Beijing Double-Crane Pharmaceutical, Beleave, Ben-Gurion University, Bendalis, Bened Biomedical, Best Choice, Better Choice Products, BevCanna, BexPharm, BGN Technologies, Bhang, Bill and Melinda Gates Foundation, Bio-Tissue, Biocept, BioClones, BioCorRx, Biodel, BioDelivery Sciences, Biodelta Nutraceuticals, Biohit, BioLight Life Sciences Investments, BiolineRX, Biological E, Biologics, Biomedical Catalyst Fund (UK), BioQ Pharma, Bioscience Enterprises, Biotop, Bioventus, BioVest, Blueberries Medical, BMG Pharmaceuticals, BMV Medica, Bonify, Bophelo Bioscience & Wellness, Boston Scientific, Boston Therapeutics, Boston Topicals, Bracco Diagnostics, Braeburn Pharmaceuticals, Breckenridge Pharmaceuticals, Brill Pharma, BRNT, BTG, Buchang Pharmaceutical, Bulu Box, Burleigh Heads Cannabis, C-Tri, C4X Discovery, Calico, Caliva, Calliditas Therapeutics, Camarus, Cambridge Commodities, Can-Fite BioPharma, Canada House Wellness Group, Canigma, Cannabics Pharmaceuticals, Cannabis Biocare, Cannabis Science, CannAcubed, CannaHoldCo, CannaKids, Cannamedical Pharma, CannAmerica Brands, CannaRoyalty, CannaSkin, Cannassure Therapeutics, Cannika, CanniMed Therapeutics, CannRx Technology, CannScience Innovations, Canntab Therapeutics, CannTrust, Cannus Partners, Cannvalate, Canopy Growth, Canopy Health Innovations, Canymed, Capcium, Cardiome Pharma, Carlina Technologies, Cascade Pure, Catalent, Catalyst Pharmaceutical Partners, Cataract & Laser Institute, CB2 Insights, CBDerma Technology, CBD Export Global, CBDistribution, CC Pharma, Cellular Dynamics International, Centric Health Resources, Centro Sperimentale del Latte, Cerebral Therapeutics, CereCare, Cerecor, Cevec Pharmaceuticals, cGreen, Changzhou Center for Biotech Development, Charles River Laboratories, Charleston Laboratories, Cheetah Medical, Chemesis, Chemi Pharmaceutical, Cheplapharm Arzneimittel, Chiesi Farmaceutici, Chinese Academy of Sciences, Choom, ChromaDex, Cincinnati Children’s Hospital Medical Center, Cingulate Therapeutics (CTx), Cipher Pharmaceuticals, Cipla Medpro, Circassia, Ciron Drugs & Pharmaceuticals, Citius Pharmaceuticals, CIVCO Radiotherapy, Clal Biotech, Clarus Therapeutics, Cleveland Diabetes Care, Clinigen, Clinipace Worldwide, CloudNine, Coating Place, Coeptis Pharmaceuticals, Colep, Collegium Pharmaceuticals, Colorado Hemp Project, Columbia Care, Compass Point Research, Concordia Healthcare, Consilient Health, Constance Therapeutics, Corium International, Corporation for Biological Research, Corvus Pharmaceuticals, Cosmo Pharmaceuticals, Courtagen Life Sciences, Crescita Therapeutics, Cristal Therapeutics, Crohn's and Colitis Foundation of America, Cronos Group, CR Pharma, CSC Pharmaceuticals, CSPC Pharmaceutical Group, CTC Group, Cumberland Emerging Technologies, Cumberland Pharmaceuticals, CURE Pharmaceutical, Currax Pharmaceuticals, CVS Caremark, CV Sciences, CyDex, Cyndea Pharma, Dabur, Daiichi Sankyo, Dalhousie University, Dare Bioscience, Dartmouth College, Dassault Systems, Dauntless Pharmaceuticals, Dekel Pharmaceuticals, Delpor, DelSiTech, Densmore Pharmaceutical, Dentamed, Department of Defense, DepoMed, DePuy, Dermata Therapeutics, Dermira, DeuteRx, Dexcel Pharma, DiaMedica, Diamyd Medical, DigiPath Solutions, Dilafor, DionyMed Brands, Diosynth, DKT, DolCas-Tenshi Bioceuticals, DolCas Biotech, Dosecann, DPT Laboratories, Dr. Reddy's Laboratories, DSG, DS Healthcare, DSM, Duchesnay, Durect, Dutch Passion Seed Company, DynamiCARE, EA Pharma, Easton Pharmaceuticals, Ecobrands, Ecolab, Eddingpharm, Editas Medicine, EffRx, Egalet, Eiger BioPharmaceuticals, Eisai, Eldan, Eli Lilly, Elis Pharmaceuticals, Elite Pharmaceuticals, Embera NeuroTherapeutics, EMD Serono, Emerald Health Therapeutics, Emerald Organic Growth, Emerge Health, Emergent BioSolutions, EMMAC Life Sciences, Emmaus Medical, Empower Clinics, EMS, Encore Dermatology, Encore Life, Endocanna Health, Endo International, EndoLogic, Endo Pharmaceuticals, Endo Ventures, EnWave, Enzymotec, EPI Health, Erytech, Espero Pharmaceuticals, Esteve, Ethicann Pharmaceuticals, Eupharmed, Eurofarma, EUSA Pharma, Everest Medicines, Evoke Pharma, Evonik Industries, Ewopharma, Exactus, Exela Pharma Sciences, Express Scripts, Eyegate Pharmaceuticals, EyePoint Pharmaceuticals, Eyevance, F2G, Faes Farma, Fagron, Famy Care, Fannin, Farmacias Magistrales, Fedecore, Femasys, Fermentalg, Ferring Pharmaceuticals, Fidia Farmaceutici, Fine Foods & Pharmaceuticals N.T.M., Fission Labs LATAM, Flexion Therapeutics, Flowerkist, Flower One, Flowonix, Flynn Pharma, Focus Laboratories, Forest Pharmaceuticals, Fosun Pharmaceutical, Fougera Pharmaceuticals, Four 20 Pharma, Fox Chase Cancer Center, Fresenius Kabi Pharmaceuticals, Front Range Biosciences, Fruit Slabs, FSD Pharma, Fudan University, Fujifilm, Fujifilm Kyowa Kirin Biologics, Futura Medical, Fuzionaire Diagnostics, Fuzionaire Radioisotope Technologies, Gaia BioPharma, Galderma, Galen, Galena Biopharma, Galenicum Health, GB Pharma Holdings, GB Sciences, Gebro Pharma, Genco Sciences, Genentech, GeneQuine Biotherapeutics, General Extract, Generex Biotechnology, Genfa Medica, Genomix Scientific, Genovi Pharmaceuticals, GenVec, Ginkgo BioWorks, Gland Pharma, Glatt Group, GlaxoSmithKline, GL Brands, Glenmark Pharmaceuticals, Global Canna Labs, Global Centers for Therapeutic Innovation, Global Damon Pharma, Gnosis Bioresearch, Good & Green, Good Start Genetics, Graminex, Grand River Aseptic Manufacturing, Green Gorilla, Grenco Science, GroupHEALTH Benefit Solutions, Grow Biotech, Grunenthal, GTCR Golder Rauner, GTEC Holdings, GTP Technology, Guerbet, Gupta Pharma, GVK Biosciences, GW Pharmaceuticals, H2-Pharma, Haisco Pharmaceutical, Halo Labs, Hamilton Health Sciences, Hammock Pharmaceuticals, Hanmi Pharmaceutical, Hannover Medical School, HanX Biopharmaceuticals, Hao Le Ku (Beijing) Infant And Maternity, Hapten Sciences, Harbin Gloria Pharmaceuticals, Harm Reduction Therapeutics, Harris, Harvest One, Healthcare Royalty Partners, Health House International, HealthWarehouse, Healthy Directions, Healthy Grain, HeavenlyRx, HEC Pharm, Helsinn Healthcare, HemispheRx Biopharma, Heritage Pharmaceuticals, Heumann Pharma Generics, Hexo, Hi-Tech Pharmacal, Hi-Tech Pharmaceuticals, Hibernation Therapeutics, Highland Pharmaceutical, High Performance Nutrition, High Tide Ventures, Hikma Pharmaceuticals, HLH BioPharma Vertriebs, HLS Therapeutics, Hollister Biosciences, HollyWeed North Cannabis, Horizon Pharma plc, Horus Pharma, Hovione, Human Biosystems, Humanetics, Huntsman, HUYA Bioscience, Hyperion Therapeutics, Hyris, Hyundai Pharmaceutical, I-Bridge Capital, IACTA Pharmaceuticals, iAnthus Capital, IBA Molecular Imaging, iBrands, ICAN, Iconic Brands, Idera Pharmaceuticals, IDIPharma, IGXBio, Ikanik Farms, Ilera Therapeutics, Immune Pharmaceuticals, Immune Therapeutics, ImmuNext, Impax Laboratories, Imperial Brands, Imperial College London, Impilo Pharma, Impression Healthcare, Imprimis Pharmaceuticals, Inceptua, India Colorada, India Globalization Capital, Indivior, Indoco, InfuTronix Solutions, Initiator Pharma, InMed Pharmaceuticals, InnoPharma, Innospec, Innovus Pharmaceuticals, Inolife Technologies, Insmed Inc, Inspirion Delivery Sciences, Integral BioSystems, Integrated Cannabis Company, Integrative Medicine, IntelGenx, Intercontinental Marketing, InterCure, International Research Center on Cannabis and Mental Health, Interprotein, Intrexon, Invekra, Invetech, Invictus MD Stategies, Ipsen, IPS Specials, iQone Healthcare, Ironshore Pharmaceuticals, Ironwood Pharmaceuticals, IsCann Group, ISIS Innovation, Island Garden, Israeli National Authority for Technological Innovation, ITM Isotopen Technologien, Itonis, J&H, Jabez Pharma, Jacksonville Pharmaceuticals, Jamieson, JAMP Pharma Group, Janssen Biotech, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Medical Isotope Technology Development, Jazz Pharmaceuticals, Jeffrey Modell Foundation, Jerome Stevens Pharmaceuticals, JHL Biotech, Jiangsu Hengrui Medicine, Johnson & Johnson, Johnson & Johnson Innovation, JQMS, Jupiter Orphan Therapeutics, Juvise Pharmaceuticals, Kadmon Pharmaceuticals, Kanabo Research, Kaneh-B, Karo Pharma, KC Pharmaceuticals, KD Pharma, KemPharm, Keygene, Khalifa Kush Enterprises, Khandelwal Laboratories, Khrysos Industries, Kindred Partners, Kinex Pharmaceuticals, Klaria, Knighton Foods, Knight Therapeutics, Kombucha Baby Brewing Company, Korea Animal Medical Science Institute, Kowa, KSF Acquisition, Kyowa Hakko Kirin, L'Oreal, Laboratorios Adler, Laboratorios Atral, Laboratorios Q Pharma, Laboratory of Malaria Immunology and Vaccinology (LMIV), Laccure, Lacer, Lachlan Pharma, Landrace Bioscience, Lannett, LatAm Clinical Trials, Leading Edge Pharms, Lee's Pharmaceutical, Legacy Biotechnologies, Leiters, Leona M and Harry B Helmsley Charitable Trust, Leonard-Meron Biosciences, LEO Pharma, Les Laboratoires Servier, Leukocare, Lexicon Pharmaceuticals, Liberty Health Sciences, Lifestyle Delivery Systems, Ligand Pharmaceuticals, Lightlake Therapeutics, Liiv Organics, Limbix, Lipidor, LipoCure, Living Proof, Los Altos Pharmaceuticals, Lotus Pharmaceuticals, Lukare Medical, Lumara Health, Lumicera Health Services, Luminarie, Lupin, Lupin Limited, Lupin Pharmaceuticals, Luqa Pharmaceuticals, Lyndra Therapeutics, MainPointe, Mallinckrodt Pharmaceuticals, Maple Leaf Green World, Marinus Pharmaceuticals, Martindale Pharma, Maruho, Masters Speciality Pharma, Maxhealth Medicine, Maxor National Pharmacy, Mayne Pharma, Mayo Clinic, MBioTeQ, McGill University, McKesson, McMaster University, McNeil Consumer Pharmaceuticals, MD Anderson Cancer Center, MD Distributor, MDRM Group (Canada), MDxHealth, Med-Aesthetic Solutions, Meda, Medac, Medacta, Meda Pharmaceuticals, MedCannAccess, Medherant, Medical Marijuana, MediCann Handels, MedicaSafe, Medicated Markets International, Medicinal Genomics, Medicines360, Medicure, Medifirst Solutions, MediGene, MedImpact Direct, MediPharm Labs, MediWound, MedPharm, MedReleaf, Medtronic, MELA Sciences, Melinta Therapeutics, Melorganics Hellas, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Meroven, Merrimack Pharmaceuticals, Merrion Pharmaceuticals, Metagenics, Methapharm, MetP Pharma, Metuchen Pharmaceuticals, MGC Pharma, Micell Technologies, Michael J Fox Foundation, Microchips Biotech, Micro Labs, Midatech, Migranade, MilanaPharm, Mino Labs, Minomic, Mission Pharmacal, Mithra Pharmaceuticals, MMJ PhytoTech, Moberg Pharma, Modern Mobility Aids, Moeller Pharma, Monopar Therapeutics, Monosol LLC, MonoSolRx, MonoSol Rx, Mor Research Applications, Moyer Foundation, MSC, MTP Material, MultiCorp International, Mundipharma, Murdoch Childrens Research Institute, Mylan Laboratories, Mylan Pharmaceuticals, MYM Nutraceuticals, MyoKardia, MYOS, Myriad Genetics, Nabis, Nabriva Therapeutics, Namaste Technologies, Nanomerics, NanoPass Technologies, Nanosphere, NanoSphere Health Sciences, Nanotherapeutics, NASA, National Center for Complementary and Integrative Health, National Green Biomed, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institutes of Health, National Kapodistrian University of Athens, Natural Sciences and Engineering Research Council of Canada, Navamedic, Navitas, NDA Partners, Nemaura Pharma, NEMUS Bioscience, Neos Therapeutics, Nephcentric, Nephron Dx, Neptune Wellness Solutions, Nestle Health Science, Neumentum, Neurim Pharmaceuticals, NeuroproteXeon, Nevada Center For Behavioral Health, NewCanna Hub, New York State, Next Frontier Biosciences, Nextleaf Solutions, Nextmune, NHL Alumni Association, Nicox, Nissan Chemical Industries, Nizo, Noden Pharma, Noramco, Nordic Pharma Group, Nordion, Norgine, NovaDel Pharma, Novalere, Novaliq, NovaMedica, Novartis, Novasep, Novel Anti-Infective Technologies, Noven Pharmaceuticals, Nrgene, NTC, Numedicus, NuMedii, Nutrasource Pharmaceutical, Nutriband, Nutrilinea, Nutritional Products International, Nuvisan group, Nuvo Pharmaceuticals, Nuvo Research, Ocean Grown Ventures, Oculus Innovative Sciences, Ocumension Therapeutics, OG DNA Genetics, OG Laboratories, Olympus Medical Systems, Omega Pharma, Omeros, Omthera Pharmaceuticals, Onco360, OncoGenex Pharmaceuticals, Onconova Therapeutics, One World Pharma, Ontario Cannabis Retail, Ontario Clinical Oncology Group, Onxeo, Ophirex, Opiant Pharmaceuticals, Opocrin S.p.A, Opsirx Pharmaceuticals, OptiBiotix, Optima Pharmazeutische, OptiNose, Or-Genix Therapeutics, Ora, Orbis, Oregon Health Sciences University, Orexigen Therapeutics, Orexo, Organigram, Organogenesis, Orimed Pharma, Orion, Orphic Therapeutics, Orsini Healthcare Specialty Pharmacy, Orthopaedic Research and Education Foundation, Osmotica Pharmaceuticals, Otifex Therapeutics, OWC Pharmaceutical Research, Oxford Pharmaceuticals, Pacira Pharmaceuticals, Pain Therapeutics, Paladin Labs, Palatin Technologies, Panaxia, PanTheryx, Paradigm, ParcelShield, Parkinson's Disease Foundation, Parnell Manufacturing, Par Pharmaceutical, Pax Labs, PDL BioPharma, Peak Health Center, Peak Performance Products, Peak Pharmaceuticals, PEAR Therapeutics, PegBio, PellePharm, Pendopharm, PeptiMimesis, Peptron, Perelman School of Medicine, Perennial, PerkinElmer, Pernix Therapeutics, Perrigo, Pfizer, Pfizer Consumer Health, Pharmabiota, PharmaChem, PharmaCielo, Pharmadrug Production, PharmaEngine, PharmaEssentia, PharmaHemp, PharmaLynk, PharmaMar, Pharmanest, Pharmascience, Pharma Solutions Peru, Pharmastrip, PharmaSwiss, Pharmathen, Pharmatronic, Pharmavite, PharmHouse, Pharming Group, Philips, Phosphate Therapeutics, PhotoMedex, PHT, Phyto Animal Health, PhytoTech Medical, Pint Pharma, Pioneer Pharma, Piramal, Piramal Healthcare, Pivotal Therapeutics, Pivot Pharmaceuticals, PlantEXT, Plethora Solutions, Pneuma Respiratory, Pohl Boskamp, Polichem, Population Council, Poxel, Pozen, Pragma Pharmaceuticals, Precisa Medical Instruments, Premier Biomedical, Premier Inc, Primex Pharmaceuticals, Probi, Profile Solutions, Progenics Pharmaceuticals, Promius Pharma, Prophase Labs, Prosonix, Protea Biosciences, Protein Sciences, Provecs Medical, Province of British Columbia, pSivida, Public Health England, Pulmatrix, Pura Naturals, Puration, Purdue Pharma, Pure Cannabis Research, PX Biosolutions, Pyramid Biosciences, Q Chip, Quanta, Quimica Europea, Quintiles, Radiomedix, Rafa Pharmaceuticals, Rafarma Pharmaceuticals, Rapid Dose Therapeutics, Raptor Pharmaceutical, RavenQuest BioMed, RCS International Investments, Real Brands, Recipharm, Reckitt Benckiser, Recordati, Redbarn Pet Products, RedHill Biopharma, ReGenX Biosciences, ReLeaf Europe, Relmada Therapeutics, Renaissance Acquisition Holdings, Reneo Pharmaceuticals, Respicardia, Reverdia, Revive Pharmaceuticals, Revive Therapeutics, Rhinomed, Rho, Rigi Healthcare, Rigi Orphan, Rising Pharmaceuticals, Rockwell Medical, Rocky Mountain Marijuana, Rogne Bioscience, Roivant Sciences, ROMEG Therapeutics, Rougier Pharma, RXi Pharmaceuticals, S.I.R.A.M., Sabal Therapeutics, SACCO, Sagent Pharmaceuticals, Salix Pharmaceuticals, Salvation Botanicals, Sandoz, Saniona, Sanofi, Santen, Santen Pharmaceutical, Saol Therapeutics, SastoMed, Satipharm, Sato Pharmaceutical, Sayre Therapeutics, Scandinavian Health, Schering-Plough, SciCann Therapeutics, SciClone Pharmaceuticals, Sciecure Pharma, Secarna Pharmaceuticals, Sedor Pharmaceuticals, Seedo, Selexis, Selvita, Sentynl Therapeutics, Seqirus, SERB Pharmaceuticals, Seren Pharmaceuticals, Serenus Biotherapeutics, Sermonix Pharmaceutical, Shanghai Dahua Pharmaceutical, Shanghai Hi-Tech Nutraceuticals, Shanxi Yabao Pharmaceutical Distribution, Shefield and Sons, Shield Therapeutics, Shionogi, Shire Pharmaceuticals, Sigma-Tau, Sigmoid, Signum Dermalogix, Simulations Plus, Sinclair IS Pharma, Sinovant Sciences, SI Pharmaceuticals, Sirona Biochem, SK Biopharmaceuticals, Skinvisible, Sloan Pharma, SMG Pharmaceuticals, Smith Medical Partners, Societe des alcools du Quebec, Soin Neuroscience, Solaris, Solasia Pharma, Soligenix, Sonoma Pharmaceuticals, Sophos Biotech, Sorin Group, Sorse technology, Sothema Laboratories, Sound Affects Life, Sound Pharmaceuticals, Sourasky Medical Center, South Coast Specialty Compounding, Southern Cross University, Southwest Research Institute, Sparsha, Spaulding Clinical Research, Speciality European Pharma, Spectrum Pharmaceuticals, SpePharm, Sproutly, St. Jude Children's Research Hospital, Starbuds, Starpharma, Starseed, SteadyMed Therapeutics, Steep Hills Labs, Stem Holdings, Stenocare, Stentys, Sterling Pharmaceutical Services, Stevens Green, StillCanna, Strategic Science and Technologies, Stratpharma, Strongbridge Biopharma, STU, SugarLeaf Labs, Sundial Growers, SunGen, Sunny Pharmtech, Sunovion Pharmaceuticals, Sun Pharmaceutical, Supernus Pharmaceuticals, Supreme Cannabis, Supreme Pharmaceuticals, Surterra Wellness, Suven Life Sciences, Swedish Orphan Biovitrum, SYGNIS Pharma, SymBio Pharmaceuticals, Symplmed Pharmaceuticals, Synbiotic Health, Syqe Medical, Tabuk Pharmaceutical, Tactical Relief, Taiho, Taisho Pharmaceutical, Takeda Pharmaceutical, Tanner Pharmaceuticals, Tanon, Tantalus Labs, Target Group, TARIS Biomedical, Taro Pharmaceuticals, Tauriga Sciences, Technion Research and Development Foundation, Technology Strategy Board (UK), Teijin, Tel Aviv University, Teligent, Temmler Group, Tenshi Kaizen, Terrace Global, TerrAscend, TerSera Therapeutics, Tesaro, TesoRx Pharma, Tetra Bio-Pharma, Teva-tuteur, Teva Pharmaceutical Industries, The Alchemists Kitchen, The Green Organic Dutchman Holdings, The Kroger, The Medicines Company, TheraCann International Benchmark, Therakine, Theramex, TherapeuticsMD, Therapeutic Solutions International, Therapix Bio, Therios Healthcare, Thermo Fisher Scientific, Thrive Cannabis, Tianjin Institute of Pharmaceutical Research, Tianyin Pharmaceutical, Tilray, TIPR-HUYA Advancing Innovative Medicines, Titan Pharmaceuticals, Tiva Bio, Toronto Innovation Acceleration Partners, Tramorgan, Transgenomic, Trendlines Group, TrialSpark, Tribute Pharmaceuticals, Trident Brands, Trigen, Trimel Pharmaceuticals, Trinity Compound Solutions, Tripex Pharmaceuticals, Tris Pharma, Trophikos, Trulieve, TSRL, UCB, Uni-Bio Science, Union Springs Pharmaceuticals, United Greeneries, Universidad CES, University College Cork, University Medical Center Groningen, University of British Columbia, University of California Berkeley, University of Colorado, University of Debrecen, University of Guelph, University of Miami, University of Mississippi, University of Nebraska, University of New South Wales, University of Oxford, University of Reading, University of Saskatchewan, University of Sherbrooke, University of Washington, Univo Pharmaceuticals, Up Cannabis, Uppsalagruppen Medical, Upsher-Smith, Urigen, Ursapharm, US Army, US Army Medical Research Institute of Infectious Diseases, US Bioservices, UTILITY Therapeutics, Valbiotis, Valeant Pharmaceuticals, Valens GroWorks, Vapium, VAYA Pharma, VDM Biochemicals, Vectura, Velo Bio, Velocity Pharmaceutical Development, Veloxis Pharmaceuticals, Venture Life, Verde Environmental Technologies, Veritas, Verix, Vernalis, Vertical Companies, Vertical Pharmaceuticals, Vici Health Sciences, Vigilant Biosciences, Viramal, Virginia Tech Carilion Research Institute, Virpax Pharmaceuticals, VitaDairy, Vital Food Processors, Vitesse Biologics, VivaCell Biotechnology Espana, Vivelix Pharmaceuticals, VIVO Cannabis, Vivus, Voisin Consulting Life Sciences, Voyager Therapeutics, vTv Therapeutics, Vyripharm, Vyrix Pharmaceuticals, Wageningen University, Walter Reed Army Institute of Research, Wanbang Biopharmaceuticals, WardMM, Wayland, Welgene Biotech, Wellness Group Pharms (WGP), Werc Shop, Westminster Pharmaceuticals, WholeScripts, Willow Biosciences, Windgap Medical, Windsor Pharmaceuticals, Wize Pharma, Womens Choice Pharmaceuticals, Woodfield Pharmaceutical, Woolsey Pharmaceuticals, World Class Extractions, Worldwide Clinical Trials, Wuhan Humanwell, Xbrane Bioscience, Xellia Pharmaceuticals, XERIS Pharmaceuticals, Xianju Pharmaceutical, XL-Protein, Yale University, Yew Bio-Pharm, Yield Growth, Yifan Pharmaceutical, Yissum Research Development, Yom Chai, Youngevity, Yukon Medical, ZAI Laboratory, ZappRx, Zelira Therapeutics, Zenabis, Zhejiang Chiral Medicine Chemicals, Zhejiang Hisun Pharmaceutical, Zogenix, Zuellig Pharma China, Zylera Pharmaceuticals, ZYUS Life Sciences